T cell responses shared among triple negative breast cancer patients
T cell responses shared among triple negative breast cancer patients
批准号:
9767747
负责人:
Jill E Slansky
金额:
$16.74万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2021-12-31
关键词:
AddressAftercareAnimal ModelAntigensAntitumor ResponseBloodBreast Cancer PatientBreast Cancer TreatmentBreast Cancer cell lineBreast Cancer survivorCD8-Positive T-LymphocytesCancer BurdenCessation of lifeCharacteristicsClinicalDiagnosisDiseaseDisease-Free SurvivalERBB2 geneEstrogen ReceptorsEstrogensFutureGenerationsGoalsHLA-A2 AntigenHigh-Throughput Nucleotide SequencingHumanImmuneImmune systemImmunotherapyIn complete remissionKnowledgeLifeMaintenanceMemoryMethodsMissionMonitorMutateMutationNeoadjuvant TherapyNeoplasm MetastasisOutcomePathologicPatientsPredictive ValueProgesteroneProgesterone ReceptorsProliferatingPublic HealthRecurrenceResearchResidual CancersRiskSpecificitySurveysSurvivorsT cell responseT memory cellT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTissuesTreatment outcomeTumor AntigensUnited States National Institutes of HealthVaccinesWomanantigen-specific T cellsbreast cancer diagnosiscancer subtypeschemotherapydesigneffective therapyimmunotherapy clinical trialsimprovedlong term memorymalignant breast neoplasmmelanomamortalitymortality riskneoantigensoutcome forecastovertreatmentperipheral bloodprognostic valuereceptorresponseshared memorysurvivorshiptriple-negative invasive breast carcinomatumorvaccine development
中文摘要
项目总结/摘要
三阴性乳腺癌(TNBC;雌激素受体,孕激素受体和HER2阴性)是乳腺癌的主要类型。
最致命的乳腺癌亚型然而,相对于其他乳腺癌亚型,
肿瘤浸润性T细胞这些T细胞的存在表明对肿瘤相关免疫反应的应答。
抗原从这种应答中,一些肿瘤特异性T细胞增殖并分化为效应细胞,
中央或组织驻留记忆T细胞。中央记忆T细胞寿命长,
检测身体中的有害抗原博尔赫斯博士和其他人最近表明,
TNBC的死亡率在诊断后5年急剧下降。但不知道哪些患者会
对治疗有成功反应以及哪些患者会复发。因此,迫切需要确定
这些T细胞可以用于未来的治疗。本文提出鉴定以下共有的T细胞受体:
五年或五年以上的TNBC幸存者和正在接受治疗的患者。提出的总体目标
研究是使用最近由Slansky开发的方法来改善TNBC患者的治疗,
德科斯基实验室。他们使用高通量测序进行了研究,发现一组TCR共同
HLA-A2+乳腺癌患者,但不是健康对照。肿瘤中共有的T细胞受体也是
在这些患者的外周血中发现。此应用程序的总体目标是使用
α-β记忆性CD8 T细胞库用于鉴定应答患者中共有的T细胞应答
并确定标准疗法对T细胞的影响。这里讨论的中心假设是,
可以鉴定出TNBC幸存妇女血液中特有的常见TCR亚群
超过5年,但没有血液的妇女谁复发。解决这一假设的具体目标是
(1)鉴定来自TNBC幸存者血液的共享记忆T细胞的T细胞受体,和(2)
确定记忆T细胞库的纵向变化,这些变化与病理性的完全免疫相关。
治疗后的反应。使用T细胞库了解长期记忆的产生
对TNBC的反应可能最终会彻底改变TNBC的治疗,因为它将为TNBC的治疗提供第一步。
鉴定可用于确定维持无疾病的关键抗原的T细胞受体
生存和其他治疗,可以提供持续的保护,防止复发多年的生存。
英文摘要
PROJECT SUMMARY/ABSTRACT
Triple negative breast cancer (TNBC; estrogen receptor-, progesterone receptor- and HER2-negative) is the
deadliest sub-type of breast cancer. However, relative to other breast cancer sub-types, TNBCs can be found
with many tumor infiltrating T cells. The presence of these T cells suggests a response to tumor-associated
antigens. From this response, some of the tumor-specific T cells proliferate and differentiate into effector,
central, or tissue-resident memory T cells. The central memory T cells are long-lived and can be found
surveying the body for the offending antigens. It was recently shown by Dr. Borges and others that the risk of
mortality from TNBC sharply decreases 5 years after diagnosis. However, it is unknown which patients will
respond successfully to therapy and which patients will recur. Thus, there is an urgent need to determine how
these T cells can be harnessed for future therapies. It is proposed here to identify shared T cell receptors of
TNBC survivors of five or more years and patients undergoing therapy. The overall goal of the proposed
research is to improve treatments for TNBC patients using a method recently developed by the Slansky and
DeKosky labs. They performed studies using high throughput sequencing, and found a panel of TCRs common
to HLA-A2+ breast cancer patients, but not healthy controls. The T cell receptors shared in tumors were also
identified in the peripheral blood of these patients. The overall objective of this application is to use the
repertoire of alpha-beta memory CD8 T cells to identify a shared T cell response among responder patients
and to determine the influence of standard therapy on T cells. The central hypothesis addressed here is that
common subsets of TCRs can be identified that are unique to the blood of women who have survived TNBC
more than 5 years, but not blood of women who have recurred. The specific aims to address this hypothesis
are: (1) to identify T cell receptors of shared memory T cells from the blood of TNBC survivors, and (2)
determine longitudinal changes in the memory T cell repertoire that correlate with a pathologic complete
response after treatment. Using the T cell repertoire to understand the generation of long-term memory
responses to TNBC may ultimately revolutionize treatment for TNBC, as it will provide the first steps toward
identification of T cell receptors that may be used to determine antigens critical to maintaining disease-free
survival and other therapies that can offer ongoing protection against recurrence for years into survivorship.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functional Activation of Low Affinity TILs
-
批准号:10520026
-
项目类别:
-
资助金额:$40.54万
-
财政年份:2018
-
负责人:Jill E Slansky
-
依托单位:
Functional Activation of Low Affinity TILs
-
批准号:10297834
-
项目类别:
-
资助金额:$40.68万
-
财政年份:2018
-
负责人:Jill E Slansky
-
依托单位:
Functional Activation of Low Affinity TILs
-
批准号:10055781
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2018
-
负责人:Jill E Slansky
-
依托单位:
Mouse Model for Antigen Specific Immunotherapy of Cancer
-
批准号:7229033
-
项目类别:
-
资助金额:$26.94万
-
财政年份:2004
-
负责人:Jill E Slansky
-
依托单位:
Mouse Model for Antigen Specific Immunotherapy of Cancer
-
批准号:6817060
-
项目类别:
-
资助金额:$28.41万
-
财政年份:2004
-
负责人:Jill E Slansky
-
依托单位:
Mouses Model for Ag.Specific Immunotherapy of Cancer
-
批准号:7076238
-
项目类别:
-
资助金额:$27.75万
-
财政年份:2004
-
负责人:Jill E Slansky
-
依托单位:
Mouse Model for Antigen Specific Immunotherapy of Cancer
-
批准号:7393729
-
项目类别:
-
资助金额:$26.94万
-
财政年份:2004
-
负责人:Jill E Slansky
-
依托单位:
Mouses Model for Ag.Specific Immunotherapy of Cancer
-
批准号:6919225
-
项目类别:
-
资助金额:$28.41万
-
财政年份:2004
-
负责人:Jill E Slansky
-
依托单位:
IMMUNODOMIANT PROPERTIES OF THE TUMOR ANTIGEN AH1
-
批准号:2708950
-
项目类别:
-
资助金额:$3.02万
-
财政年份:1999
-
负责人:Jill E Slansky
-
依托单位:
IMMUNODOMIANT PROPERTIES OF THE TUMOR ANTIGEN AH1
-
批准号:6055747
-
项目类别:
-
资助金额:$3.84万
-
财政年份:1999
-
负责人:Jill E Slansky
-
依托单位:
海外基金